Six challenges
Six problems an enterprise has to solve before agents work on proprietary or regulated data, each with the answers that address it. For what Atlas has built against them, with an honest status for each, see technical evidence.
Protect confidential data
Prompts, files and retrieved context can carry unpublished data, assay results and partner material to external models. Decide where models run, under which terms, and what content an agent may read.
Verify AI-generated conclusions
In regulated science an unsupported number or citation is worse than no answer. A prediction needs a stated evidence level, a dated lock and a named person who decides what it is used for.
Govern autonomous agents
Every agent needs an owner, an entry in an inventory and a defined intended use. Governance decides who approves an agent, who reviews its work, how it changes and how it is retired.
- What Is AI Agent Governance in Life Sciences and GxP?
- What Is an AI Governance Control Plane for Agents in Life-Science R&D?
- Who Owns AI Agent Governance in a Biotech? Roles and a RACI for QA, IT, R&D and Legal
- AI Agent Inventory for Pharma R&D: 8 Core Fields
- How to Run a First AI Agent Pilot in a Biotech: A 90-Day Plan
- What Is ISO/IEC 42001 and Does a Biotech Need It?
- How Does the NIST AI RMF Apply to AI Agents in Pharma R&D?
Identity and permissions
An agent that can read, call tools and write records is a privileged identity. Give it the least access it needs, and keep signatures and approvals with people.
Regulatory and validation requirements
Where AI touches GxP records, existing rules such as 21 CFR Part 11 and EU GMP Annex 11 apply, and draft EU GMP Annex 22 and the ISPE GAMP AI guide add AI-specific guidance. Validation, change control and supplier qualification follow intended use and risk.
- Does 21 CFR Part 11 Apply to AI Tools and Agents?
- How Do You Validate an AI Agent Used in a GxP Process?
- What Does EU GMP Annex 22 (Artificial Intelligence) Mean for AI Agents?
- ISPE GAMP AI Guide: What's Public on Validation
- Change Control for AI Models and Prompts in GxP: When Does an Update Need Revalidation?
- Checking AI Agent Actions in GxP: Audit Trail Review, Access Review and Periodic Review
- Qualifying an AI Vendor as a GxP Supplier: What QA Should Assess and Put in the Quality Agreement
- How Does FDA's AI Credibility Assessment Framework Work?
- Does the EU AI Act Apply to AI Used in Drug Discovery R&D?
Reconstruct and audit agent actions
When an agent acts, you need to reconstruct what it saw, what it produced and who approved it, for auditors, regulators and your own investigations. That depends on what the audit trail records, how long it is kept and how errors are handled.
Guides by topic
Every answer above, grouped into four topics, with a one-line summary of each.
Security
Keeping research data inside approved boundaries and limiting what agents can reach.
- Keeping Proprietary Research Data Out of External AI Models
How biotech and pharma teams can use external AI models without unpublished data, assay results or partner material leaving their control: business-grade terms, a gateway policy, a proprietary data registry and labels. - Own Cloud Tenant or Vendor API? AI Data-Control Trade-offs for Biotech
Vendor AI API vs a model in your own cloud (Azure, Bedrock, Vertex AI) vs open-weight models: training, retention, abuse monitoring, residency and effort. - Prompt Injection Risk for Research AI Agents
Prompt injection is text that changes what an AI model does. Why research agents reading papers, files and web pages are exposed, and how to limit the damage. - What to Check Before Giving an AI Agent Access to Your ELN or LIMS
Checklist before an AI agent gets ELN or LIMS access: read vs write scopes, identity, least privilege, locked records, audit trail, test instance, kill switch. - How to Secure AI Agents in Life-Science R&D
How biotech, pharma and CRO teams secure and govern AI agents in R&D: least access, human approval, full logging, and what changes under GxP.
Trust and validation
How to tell whether an AI conclusion deserves to be relied on.
- What Evidence Should AI Biology Predictions Meet?
An AI biology prediction should carry an evidence level, a pre-registered lock, an out-of-distribution number and a documented miss. Here is the standard. - What Is Pre-Registration of Predictions?
Pre-registration locks a prediction, its endpoint and its analysis plan before the answer exists. Why it is the only thing that separates predictive skill from hindsight in AI biology. - Human-in-the-Loop AI in Drug Discovery
Human-in-the-loop AI means named decisions a model may never make alone. Here is how to define those decision rights so oversight is real, not decorative. - How to Evaluate an AI Drug-Discovery Vendor
The questions that separate a working model from a good deck: out-of-distribution performance, a dated prediction, a documented miss, a named context of use, and the base rate the claim has to beat.
Governance
Owners, inventories, change and incidents across an agent's life.
- What Is AI Agent Governance in Life Sciences and GxP?
AI agent governance in life sciences and GxP: inventory, owners, permissions, human approval, logging, testing and change control, with GAMP 5 and FDA CSA. - What Is an AI Governance Control Plane for Agents in Life-Science R&D?
An AI governance control plane holds agent policy in one place and enforces it where agents act: identity, models, data, tools, decisions and evidence. - Who Owns AI Agent Governance in a Biotech? Roles and a RACI for QA, IT, R&D and Legal
Who approves an AI agent, owns its intended use, reviews its outputs, handles incidents and retires it: a RACI for QA, IT, R&D and legal, discovery vs GxP. - AI Agent Inventory for Pharma R&D: 8 Core Fields
AI agent inventory for pharma R&D governance: owner, intended use, data access, model version, autonomy, human sign-offs, GxP status and review date. - How to Run a First AI Agent Pilot in a Biotech: A 90-Day Plan
A week-by-week 90-day plan for a first AI agent pilot in a biotech: non-GxP use case, data scope, sandbox, success criteria, human review and a go/no-go gate. - What Is ISO/IEC 42001 and Does a Biotech Need It?
ISO/IEC 42001 sets requirements for an AI management system. ISO says certification is voluntary. When a biotech may need it; why it is not GxP validation. - How Does the NIST AI RMF Apply to AI Agents in Pharma R&D?
Atlas Bio's mapping of the voluntary NIST AI RMF functions to AI agent work in pharma R&D, with NIST AI 600-1 action IDs and draft Annex 22 and ISO/IEC 42001 overlaps. - Change Control for AI Models and Prompts in GxP: When Does an Update Need Revalidation?
Change control for AI in GxP: model versions, vendor updates, prompt edits and retrieval changes, with risk-based triggers and a revalidation decision table. - Checking AI Agent Actions in GxP: Audit Trail Review, Access Review and Periodic Review
Periodic review of a GxP AI agent: risk-based frequency, performance vs acceptance criteria, audit trail and access review, changes, incidents, supplier models. - When an AI Agent Gets It Wrong: Deviations, CAPA and Incident Handling for AI in GxP and R&D
AI agent errors in GxP and R&D: deviation vs research error, containment and rollback, root-cause categories, CAPA linked to change control, what to record.
Regulated life sciences
Record rules, validation and regulator guidance where AI touches GxP work.
- Does 21 CFR Part 11 Apply to AI Tools and Agents?
Yes, when an AI tool or agent creates, changes, keeps or transmits an electronic record FDA rules require, or one submitted to FDA. The AI cannot sign. - Can an AI Agent Sign or Approve a GxP Record?
Why an AI agent cannot sign a GxP record under 21 CFR Part 11 Subpart C or EU GMP Annex 11, what it can do instead, and what it should record. - ALCOA+ for Records Created or Changed by AI
How each ALCOA+ attribute applies when an AI tool or agent creates or changes a GxP record: identity, inputs, model version, original output and review. - Audit Trails for AI Agents in Regulated Research
What an AI-agent audit trail should capture in GxP work: log-field table, ALCOA++ mapping and EU GMP Annex 11 clause map, from FDA, EMA and ICH sources. - GxP Data Retention: AI Agent Logs, Audit Trails
No GxP rule sets a retention period specifically for AI agent logs; 21 CFR 11.10(e) ties audit trails to their records, whose rule sets the minimum. - How Do You Validate an AI Agent Used in a GxP Process?
Validating an AI agent for GxP: intended use, risk assessment, risk-based testing, acceptance criteria for variable outputs, human review and revalidation. - What Does EU GMP Annex 22 (Artificial Intelligence) Mean for AI Agents?
Draft EU GMP Annex 22 on AI, clause by clause: its scope, the LLM exclusion, intended use, test data, human review, Annex 11 and the EU AI Act. - ISPE GAMP AI Guide: What's Public on Validation
Summary of ISPE's public material on the GAMP AI Guide: how it frames GxP AI validation, risk, life cycle, data governance and what that material omits. - How Does FDA's AI Credibility Assessment Framework Work?
The seven steps of FDA's January 2025 draft guidance on AI to support regulatory decisions for drugs and biologics, built around context of use and model risk. - Does the EU AI Act Apply to AI Used in Drug Discovery R&D?
Article 2(6) excludes AI built and used solely for scientific R&D; other tools used in research stay in scope. High-risk routes, dates and duties. - Qualifying an AI Vendor as a GxP Supplier: What QA Should Assess and Put in the Quality Agreement
How QA qualifies an AI vendor as a GxP supplier: risk-based assessment, model versioning, training data, audit trails, and the quality-agreement clauses.
AI agent controls checklist, organized by NIST AI RMF function
24 controls for AI agents in life-science R&D, grouped under the four functions of the NIST AI Risk Management Framework (AI RMF 1.0, NIST AI 100-1, January 2023): Govern, Map, Measure and Manage. Each item names the AI RMF subcategory Atlas Bio mapped it to and quotes that subcategory’s wording. Mark each item and the totals for each function update as you go. For how the four functions apply to agent work more broadly, see How Does the NIST AI RMF Apply to AI Agents in Pharma R&D?
Self-check tally, not a conformity score. Items marked not applicable are left out of each total.
Govern
Policies, owners, roles and third-party rules. NIST calls Govern a cross-cutting function that informs the other three.
- The rules that apply to each agent’s use are identified and written down. For example, GxP predicate rules and 21 CFR Part 11 and/or EU GMP Annex 11 where the agent creates, modifies, maintains, retrieves or transmits GxP records, or is used in a GxP-regulated activity, plus data-protection law and partner or licence terms for the data it reads. See: Does 21 CFR Part 11 Apply to AI Tools and Agents?NIST AI RMF 1.0 GOVERN 1.1: “Legal and regulatory requirements involving AI are understood, managed, and documented.”
- Every AI agent is listed in an inventory with a named owner. Include agents that arrive as features of an ELN, LIMS or office suite, not only the ones you build. See: AI Agent Inventory for Pharma R&D: 8 Core FieldsNIST AI RMF 1.0 GOVERN 1.6: “Mechanisms are in place to inventory AI systems and are resourced according to organizational risk priorities.”
- Who approves an agent, who reviews its output, who handles its incidents and who retires it is documented. See: Who Owns AI Agent Governance in a Biotech? Roles and a RACI for QA, IT, R&D and Legal.NIST AI RMF 1.0 GOVERN 2.1: “Roles and responsibilities and lines of communication related to mapping, measuring, and managing AI risks are documented and are clear to individuals and teams throughout the organization.”
- The actions an agent may never take, and those it may take only after a named person’s review, are listed. For example, an agent never applies an electronic signature or approves a GxP record; a person does, under their own credentials. Nor does an agent change a locked record. See: Can an AI Agent Sign or Approve a GxP Record?NIST AI RMF 1.0 GOVERN 3.2: “Policies and procedures are in place to define and differentiate roles and responsibilities for human-AI configurations and oversight of AI systems.”
- AI vendors and model providers are assessed before research data reaches them. Cover training on your data, retention, sub-processors, where data is processed, and whether partner or in-licensed material may be sent at all. For GxP use, add supplier qualification and a quality agreement that includes change notification. See: Qualifying an AI Vendor as a GxP Supplier: What QA Should Assess and Put in the Quality Agreement.NIST AI RMF 1.0 GOVERN 6.1: “Policies and procedures are in place that address AI risks associated with third-party entities, including risks of infringement of a third-party’s intellectual property or other rights.”
- There is a written way to retire an agent. Revoke its credentials and tool access, and keep its records and logs for the retention period that applies to them, in a form that can still be read and retrieved after the agent and its platform are gone. See: GxP Data Retention: AI Agent Logs, Audit Trails.NIST AI RMF 1.0 GOVERN 1.7: “Processes and procedures are in place for decommissioning and phasing out AI systems safely and in a manner that does not increase risks or decrease the organization’s trustworthiness.”
Map
The context: intended use, limits, oversight and the components around each agent.
- Each agent’s intended use is written down. The research task, the data it may read, who uses it, and whether it is discovery work, produces data that may later support a regulatory submission, or touches GxP records. See: What Is AI Agent Governance in Life Sciences and GxP?NIST AI RMF 1.0 MAP 1.1: “Intended purposes, potentially beneficial uses, context-specific laws, norms and expectations, and prospective settings in which the AI system will be deployed are understood and documented. …”
- The agent’s known limits are documented for its users, with how its output is to be checked before anyone acts on it.NIST AI RMF 1.0 MAP 2.2: “Information about the AI system’s knowledge limits and how system output may be utilized and overseen by humans is documented. …”
- For scientific tasks, the test design and test data are chosen for the question the agent will actually face. Check that the data are representative and suitable for the task, and that what you measure really reflects the scientific claim. See: What Is Pre-Registration of Predictions?NIST AI RMF 1.0 MAP 2.3: “Scientific integrity and TEVV considerations are identified and documented, including those related to experimental design, data collection and selection (e.g., availability, representativeness, suitability), system trustworthiness, and construct validation.”
- A human review step is defined for each output that feeds a decision or a record: who reviews it and what they check. See: Human-in-the-Loop AI in Drug Discovery.NIST AI RMF 1.0 MAP 3.5: “Processes for human oversight are defined, assessed, and documented in accordance with organizational policies from the GOVERN function.”
- The controls around each component are listed: which model, which tools and connectors, and what data the agent can and cannot reach. For example, a gateway or policy that keeps unpublished data and partner material away from models not approved for it. See: Keeping Proprietary Research Data Out of External AI Models.NIST AI RMF 1.0 MAP 4.2: “Internal risk controls for components of the AI system, including third-party AI technologies, are identified and documented.”
Measure
Testing, evaluation and monitoring of the risks found in Map.
- Before testing starts, the test set, the acceptance criteria and the evaluation tools are documented, and results are recorded against them. See: How Do You Validate an AI Agent Used in a GxP Process?NIST AI RMF 1.0 MEASURE 2.1: “Test sets, metrics, and details about the tools used during TEVV are documented.”
- Performance is tested on material like the agent will see in use, including the unusual and edge cases it will meet. Inputs representative of your real document types and assay formats (synthetic or approved internal copies), not only the demo set. See: What Evidence Should AI Biology Predictions Meet?NIST AI RMF 1.0 MEASURE 2.3: “AI system performance or assurance criteria are measured qualitatively or quantitatively and demonstrated for conditions similar to deployment setting(s). Measures are documented.”
- Security is tested against the agent’s real inputs, including prompt injection hidden in papers, files or web pages it reads. See: Prompt Injection Risk for Research AI Agents.NIST AI RMF 1.0 MEASURE 2.7: “AI system security and resilience – as identified in the MAP function – are evaluated and documented.”
- Where an agent can reach personal data, such as clinical or patient-level data, including coded or pseudonymised data, its privacy risk is examined and documented.NIST AI RMF 1.0 MEASURE 2.10: “Privacy risk of the AI system – as identified in the MAP function – is examined and documented.”
- You have checked that you can reconstruct what the agent read, what it produced or changed, when, with which model version and configuration, and who reviewed or approved it. If the audit trail cannot answer those questions, the gap is recorded. See: Audit Trails for AI Agents in Regulated Research.NIST AI RMF 1.0 MEASURE 2.8: “Risks associated with transparency and accountability – as identified in the MAP function – are examined and documented.”
- Assessments include people who did not build the agent, such as QA or a domain scientist.NIST AI RMF 1.0 MEASURE 1.3: “Internal experts who did not serve as front-line developers for the system and/or independent assessors are involved in regular assessments and updates. …”
- The agent’s behaviour is monitored in production against what was tested. For example, the error rate found in human review, tracked over time.NIST AI RMF 1.0 MEASURE 2.4: “The functionality and behavior of the AI system and its components – as identified in the MAP function – are monitored when in production.”
Manage
Decisions, responses, switch-off, vendor changes and incidents.
- A go/no-go decision is recorded before an agent moves from pilot to wider use. See: How to Run a First AI Agent Pilot in a Biotech: A 90-Day Plan.NIST AI RMF 1.0 MANAGE 1.1: “A determination is made as to whether the AI system achieves its intended purposes and stated objectives and whether its development or deployment should proceed.”
- Risks you have accepted rather than fixed are written down, with who accepted them, and shared with the agent’s users.NIST AI RMF 1.0 MANAGE 1.4: “Negative residual risks (defined as the sum of all unmitigated risks) to both downstream acquirers of AI systems and end users are documented.”
- A named person has a tested way to switch an agent off or roll it back if it behaves outside its intended use.NIST AI RMF 1.0 MANAGE 2.4: “Mechanisms are in place and applied, and responsibilities are assigned and understood, to supersede, disengage, or deactivate AI systems that demonstrate performance or outcomes inconsistent with intended use.”
- Changes on the vendor side, such as a new model version or changed terms, are tracked and trigger a review. A hosted model can change behind an unchanged model name. See: Change Control for AI Models and Prompts in GxP: When Does an Update Need Revalidation?NIST AI RMF 1.0 MANAGE 3.1: “AI risks and benefits from third-party resources are regularly monitored, and risk controls are applied and documented.”
- A post-deployment plan covers monitoring, user feedback, override, incident response, recovery and change management. See: Checking AI Agent Actions in GxP: Audit Trail Review, Access Review and Periodic Review.NIST AI RMF 1.0 MANAGE 4.1: “Post-deployment AI system monitoring plans are implemented, including mechanisms for capturing and evaluating input from users and other relevant AI actors, appeal and override, decommissioning, incident response, recovery, and change management.”
- Agent errors and incidents are logged, investigated and reported to the people affected, with fixes tracked. In GxP work, include an impact assessment on affected records or studies, and where the error is a deviation, handle it through your deviation and CAPA process. See: When an AI Agent Gets It Wrong: Deviations, CAPA and Incident Handling for AI in GxP and R&D.NIST AI RMF 1.0 MANAGE 4.3: “Incidents and errors are communicated to relevant AI actors, including affected communities. Processes for tracking, responding to, and recovering from incidents and errors are followed and documented.”
Source for every subcategory ID and quotation: NIST, Artificial Intelligence Risk Management Framework (AI RMF 1.0), NIST AI 100-1, January 2023, Tables 1–4. Quotations ending in … are the first sentence or clause of a longer subcategory. NIST’s suggested actions for each subcategory are in the AI RMF Playbook; framework overview: NIST AI Risk Management Framework. NIST’s Playbook page states that AI RMF 1.0 is being updated, so subcategory IDs and wording may change in a later version; this checklist follows version 1.0.
Downloads
Templates and checklists published with the answers. No form or sign-up. Free to copy and use inside your organization. General guidance, not regulatory advice.
- AI vendor data-handling questionnaire for life-science R&D. 32 questions to put to an AI vendor before research data reaches its product. Download (Excel) · Download (PDF)
From: How to Evaluate an AI Drug-Discovery Vendor - Audit-trail and access-control checklist for AI agents in GxP research. One printable checklist. Download (PDF)
From: Audit Trails for AI Agents in Regulated Research - Validation plan outline for an AI agent in a GxP process. A fill-in outline. Download (PDF) · Download (Word)
From: How Do You Validate an AI Agent Used in a GxP Process? - AI agent inventory register template. The register, the field-to-framework mapping with sources, and field guidance. Download (Excel)
From: AI Agent Inventory for Pharma R&D: 8 Core Fields
Start with an AI security and governance assessment
Understand how your organization uses AI today, where confidential information may be exposed, and which controls are needed before expanding to autonomous workflows.
Request an AI security assessment →